The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma

Five cases were treated by adding daily low-dose thalidomide (50 mg) to bortezomib and dexamethasone therapy for refractory multiple myeloma. This therapy was effective in four cases, with an improvement of bone pain and regression of M-protein. One case was treated with cyclophosphamide, thalidomid...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Shigeo, Kuroha, Takashi, Yano, Toshio, Sato, Naoko, Furukawa, Tatsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109573/
https://www.ncbi.nlm.nih.gov/pubmed/27746443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109573/
https://www.ncbi.nlm.nih.gov/pubmed/27746443

Ejemplares similares